BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $8.95 Million Stock Position in Illumina, Inc. $ILMN

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 24.9% in the second quarter, HoldingsChannel reports. The firm owned 93,807 shares of the life sciences company’s stock after purchasing an additional 18,672 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Illumina were worth $8,950,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. grew its stake in Illumina by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after buying an additional 99 shares during the last quarter. Moors & Cabot Inc. boosted its holdings in shares of Illumina by 2.5% in the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock worth $465,000 after acquiring an additional 145 shares in the last quarter. Arkadios Wealth Advisors boosted its holdings in shares of Illumina by 1.7% in the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after acquiring an additional 157 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Illumina by 3.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 164 shares in the last quarter. Finally, Whipplewood Advisors LLC raised its position in Illumina by 22.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 929 shares of the life sciences company’s stock valued at $89,000 after purchasing an additional 169 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Illumina stock opened at $116.86 on Wednesday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a market cap of $17.96 billion, a PE ratio of 14.79, a PEG ratio of 2.34 and a beta of 1.40. The company’s 50-day moving average is $99.18 and its two-hundred day moving average is $93.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a report on Tuesday, September 2nd. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a report on Friday, July 11th. Finally, Barclays upped their target price on shares of Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research report on Friday. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.